醫藥股拉昇,創新藥ETF超漲3%
格隆匯10月13日丨低迷許久的醫藥股,迎來大反攻。百濟神州大漲近13%,華東醫藥、藥石科技漲超10%,藥明康德漲超6%。創新藥企ETF、創新藥50ETF、創新藥產業ETF、創新藥ETF均漲超3%。消息面上,藥明康德發佈三季報預吿,預計前三季實現淨利潤73.78億元,淨利潤同比增長107.12%。華東醫藥公吿稱,預計前三季度淨利潤19.71億元-20.66億元,同比增長4.00%-9.00%。當下關於醫藥板塊是否迎來反轉的爭議較大。看好醫藥行業的認為醫藥估值已較為充分反映悲觀預期,邊際上出現積極因素往往容易帶來股價反彈,不宜再度外推悲觀預期,中期佈局機會可能逐步顯現。而有基金經理則持有不同觀點,認為醫藥板塊基本面缺乏明顯的向上邏輯,短期內或尚難大幅反轉。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.